Coldstream Capital Management Inc. Buys 259 Shares of Becton, Dickinson and Company (NYSE:BDX)

Coldstream Capital Management Inc. lifted its stake in Becton, Dickinson and Company (NYSE:BDX) by 6.6% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 4,168 shares of the medical instruments supplier’s stock after purchasing an additional 259 shares during the period. Coldstream Capital Management Inc.’s holdings in Becton, Dickinson and Company were worth $946,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Vanguard Group Inc. boosted its position in shares of Becton, Dickinson and Company by 0.7% in the 4th quarter. Vanguard Group Inc. now owns 26,743,052 shares of the medical instruments supplier’s stock worth $6,067,196,000 after purchasing an additional 184,288 shares during the last quarter. T. Rowe Price Investment Management Inc. lifted its holdings in Becton, Dickinson and Company by 36.1% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 12,126,707 shares of the medical instruments supplier’s stock worth $2,751,187,000 after acquiring an additional 3,219,317 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Becton, Dickinson and Company by 1.1% during the fourth quarter. Geode Capital Management LLC now owns 6,351,537 shares of the medical instruments supplier’s stock worth $1,437,161,000 after acquiring an additional 66,024 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its holdings in Becton, Dickinson and Company by 15.1% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 6,175,899 shares of the medical instruments supplier’s stock worth $1,401,126,000 after acquiring an additional 810,345 shares in the last quarter. Finally, First Eagle Investment Management LLC lifted its holdings in Becton, Dickinson and Company by 31.4% during the fourth quarter. First Eagle Investment Management LLC now owns 4,426,022 shares of the medical instruments supplier’s stock worth $1,004,132,000 after acquiring an additional 1,057,879 shares in the last quarter. 86.97% of the stock is currently owned by institutional investors.

Insider Activity at Becton, Dickinson and Company

In related news, EVP Michael David Garrison sold 479 shares of Becton, Dickinson and Company stock in a transaction dated Wednesday, April 9th. The stock was sold at an average price of $197.28, for a total value of $94,497.12. Following the sale, the executive vice president now owns 4,887 shares of the company’s stock, valued at approximately $964,107.36. The trade was a 8.93 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Richard Byrd sold 1,940 shares of the business’s stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $224.91, for a total value of $436,325.40. Following the transaction, the executive vice president now directly owns 7,411 shares in the company, valued at approximately $1,666,808.01. This trade represents a 20.75 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 3,578 shares of company stock valued at $795,986. 0.36% of the stock is owned by insiders.

Analyst Ratings Changes

Several research analysts have weighed in on the company. StockNews.com upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Wednesday, April 2nd. Barclays reduced their target price on Becton, Dickinson and Company from $279.00 to $261.00 and set an “overweight” rating on the stock in a report on Monday, April 7th. Finally, Piper Sandler reduced their target price on Becton, Dickinson and Company from $280.00 to $260.00 and set an “overweight” rating on the stock in a report on Wednesday, April 23rd. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $272.86.

Becton, Dickinson and Company Stock Performance

Shares of Becton, Dickinson and Company stock opened at $205.10 on Tuesday. The firm has a market cap of $58.89 billion, a price-to-earnings ratio of 34.07, a price-to-earnings-growth ratio of 1.63 and a beta of 0.35. The stock’s 50-day moving average is $218.06 and its 200-day moving average is $226.98. Becton, Dickinson and Company has a one year low of $193.03 and a one year high of $251.99. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.13 and a quick ratio of 0.63.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 EPS for the quarter, beating analysts’ consensus estimates of $3.00 by $0.43. Becton, Dickinson and Company had a return on equity of 15.74% and a net margin of 8.47%. Equities analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company announced that its Board of Directors has initiated a stock repurchase plan on Tuesday, January 28th that allows the company to buyback 10,000,000 shares. This buyback authorization allows the medical instruments supplier to buy shares of its stock through open market purchases. Shares buyback plans are generally a sign that the company’s board of directors believes its stock is undervalued.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.